Dennis Jones | Profiles RNS

Dennis Jones, PhD

Assistant Professor

Boston University Chobanian & Avedisian School of Medicine

Pathology & Laboratory Medicine

PhD, Yale University School of Medicine
BS, Morehouse College

Websites

	LinkedIn
	Jones Laboratory
	Immunology Training Program Faculty
	Google Scholar
	My NCBI
	BUSM

ORCID : 0000-0002-1401-9701

Dennis Jones, PhD is an Assistant Professor of Pathology & Laboratory Medicine at the Chobanian and Avedisian School of Medicine.Our research focuses on understanding how tumors impact the functionality of blood vessels, which are essential for immune cells, such as T cells, to infiltrate tumors. Our previous studies have found that tumors can cause the compression and dysfunction of blood vessels, which ultimately limits T cell entry into the tumor. Therefore, our lab aims to develop approaches to improve vascular function within tumors, with the goal of increasing T cell entry. In combination, we will use immunotherapy to enhance the killing ability of T cells. Currently, we are testing this combination therapy in preclinical models. Our ultimate goal is to improve outcomes for patients with metastatic breast cancer.
Our lab is comprised of a multidisciplinary team of trainees with expertise in cancer biology, immunology, and vascular biology. We employ a range of techniques, including in vitro and in vivo experiments, imaging, and molecular and cellular biology assays, to better understand the complex mechanisms underlying tumor-induced vascular dysfunction and immune suppression.

Diversity, Equity, Inclusion and Accessibility

As a scientist from a historically underrepresented minority group, promoting diversity and inclusion within biomedical research is a deeply ingrained part of my values and mission.
My efforts to expose other underrepresented persons to research began during my graduate studies. Over three years, I co-coordinated an NIH-funded summer research program that was designed to provide research experiences for historically underrepresented minorities. I managed research experiences for 35 of the 70 undergraduates who participated, and 93% of these students went on to graduate from college, with nearly one-quarter pursuing PhD and MD/PhD programs. As a postdoctoral fellow, I spent three summers working with high school and college students enrolled in the NCI’s CURE program at the Dana Farber Cancer Institute. As a faculty member at Boston University, I have continued my commitment to increasing diversity and inclusion by hosting historically underrepresented students in my laboratory through BU STaRS Program, PREP Program, and through the Medical Sciences and Education Department's partnership with local public high schools.
I believe in the importance of Black representation in academia to inspire confidence among trainees of color, and I intentionally maintain visibility through profile features and speaking engagements. I strive to create a more inclusive research culture by fostering a welcoming and encouraging space in my own laboratory where all individuals, including those from historically underrepresented groups, can do great science. While my race adds to the diversity in science, my primary focus and passion is to achieve significant breakthroughs in breast cancer treatment. I hope that my scientific productivity and commitment to diversity and inclusion will inspire other historically underrepresented scientists in their academic pursuits.

Graduate Faculty (Primary Mentor of Grad Students)
Boston University Chobanian & Avedisian School of Medicine, Graduate Medical Sciences

Member
Boston University
BU-BMC Cancer Center

BU Research

Improving anti-breast cancer immunity by targeting solid stress
07/01/2022 - 06/30/2024 (Subcontract PI)
American Association for Cancer Research Breast Cancer ResFdn

Targeting breast cancer plasticity and immunosuppression in metastatic lymph nodes
07/07/2021 - 07/06/2023 (PI)
METAvivor

Understanding the mechanisms of immune suppression in lymph node metastases
09/30/2018 - 08/31/2022 (PI)
NIH/National Cancer Institute
5K22CA230315-03

Title

Yr	Title	Project-Sub Proj	Pubs

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis Copy PMIDs To Clipboard

Arroyo-Ataz G, Jones D. Dissection of murine collecting lymphatic vessels for imaging, single-cell analysis, and tissue culture of lymphatic muscle cells. STAR Protoc. 2022 Dec 16; 3(4):101800. PMID: 36353362; PMCID: PMC9637822; DOI: 10.1016/j.xpro.2022.101800;

Jones D, Wang Z, Chen IX, Zhang S, Banerji R, Lei PJ, Zhou H, Xiao V, Kwong C, van Wijnbergen JWM, Pereira ER, Vakoc BJ, Huang P, Nia HT, Padera TP. Solid stress impairs lymphocyte infiltration into lymph-node metastases. Nat Biomed Eng. 2021 12; 5(12):1426-1436.View Related Profiles.

Jones, Dennis
Nia, Hadi

PMID: 34282290; PMCID: PMC8678215; DOI: 10.1038/s41551-021-00766-1;

Jana S, Muscarella RA, Jones D. The Multifaceted Effects of Breast Cancer on Tumor-Draining Lymph Nodes. Am J Pathol. 2021 08; 191(8):1353-1363. PMID: 34043978; PMCID: PMC8351123; DOI: 10.1016/j.ajpath.2021.05.006;

Saeboe AM, Nikiforov AY, Toufanian R, Kays JC, Chern M, Casas JP, Han K, Piryatinski A, Jones D, Dennis AM. Extending the Near-Infrared Emission Range of Indium Phosphide Quantum Dots for Multiplexed In Vivo Imaging. Nano Lett. 2021 04 14; 21(7):3271-3279.View Related Profiles.

Dennis, Allison
Jones, Dennis

PMID: 33755481; PMCID: PMC8243857; DOI: 10.1021/acs.nanolett.1c00600;

Gustine JN, Jones D. Immunopathology of Hyperinflammation in COVID-19. Am J Pathol. 2021 01; 191(1):4-17. PMID: 32919977; PMCID: PMC7484812; DOI: 10.1016/j.ajpath.2020.08.009;

Jones D. Parallels of Resistance between Angiogenesis and Lymphangiogenesis Inhibition in Cancer Therapy. Cells. 2020 03 20; 9(3). PMID: 32244922; PMCID: PMC7140636; DOI: 10.3390/cells9030762;

Liu T, Li Y, Su H, Zhang H, Jones D, Zhou HJ, Ji W, Min W. Nuclear localization of the tyrosine kinase BMX mediates VEGFR2 expression. J Cell Mol Med. 2020 01; 24(1):126-138. PMID: 31642192; PMCID: PMC6933376; DOI: 10.1111/jcmm.14663;

Zhao Y, Cao J, Melamed A, Worley M, Gockley A, Jones D, Nia HT, Zhang Y, Stylianopoulos T, Kumar AS, Mpekris F, Datta M, Sun Y, Wu L, Gao X, Yeku O, Del Carmen MG, Spriggs DR, Jain RK, Xu L. Losartan treatment enhances chemotherapy efficacy and reduces ascites in ovarian cancer models by normalizing the tumor stroma. Proc Natl Acad Sci U S A. 2019 02 05; 116(6):2210-2219.View Related Profiles.

Jones, Dennis
Nia, Hadi

PMID: 30659155; PMCID: PMC6369817; DOI: 10.1073/pnas.1818357116;

Liao S, Bouta EM, Morris LM, Jones D, Jain RK, Padera TP. Inducible Nitric Oxide Synthase and CD11b+Gr1+ Cells Impair Lymphatic Contraction of Tumor-Draining Lymphatic Vessels. Lymphat Res Biol. 2019 06; 17(3):294-300. PMID: 30358484; PMCID: PMC6589499; DOI: 10.1089/lrb.2018.0013;

Pereira ER, Kedrin D, Seano G, Gautier O, Meijer EFJ, Jones D, Chin SM, Kitahara S, Bouta EM, Chang J, Beech E, Jeong HS, Carroll MC, Taghian AG, Padera TP. Lymph node metastases can invade local blood vessels, exit the node, and colonize distant organs in mice. Science. 2018 03 23; 359(6382):1403-1407. PMID: 29567713; PMCID: PMC6002772; DOI: 10.1126/science.aal3622;

Showing 10 of 27 results. Show More

Jones D, Pereira ER, Padera TP. Growth and Immune Evasion of Lymph Node Metastasis. Front Oncol. 2018; 8:36. PMID: 29527513; PMCID: PMC5829610; DOI: 10.3389/fonc.2018.00036;

Jones D, Meijer EFJ, Blatter C, Liao S, Pereira ER, Bouta EM, Jung K, Chin SM, Huang P, Munn LL, Vakoc BJ, Otto M, Padera TP. Methicillin-resistant Staphylococcus aureus causes sustained collecting lymphatic vessel dysfunction. Sci Transl Med. 2018 01 17; 10(424). PMID: 29343625; PMCID: PMC5953194; DOI: 10.1126/scitranslmed.aam7964;

Meijer EFJ, Blatter C, Chen IX, Bouta E, Jones D, Pereira ER, Jung K, Vakoc BJ, Baish JW, Padera TP. Lymph node effective vascular permeability and chemotherapy uptake. Microcirculation. 2017 08; 24(6). PMID: 28510992; PMCID: PMC5706450; DOI: 10.1111/micc.12381;

Nia HT, Liu H, Seano G, Datta M, Jones D, Rahbari N, Incio J, Chauhan VP, Jung K, Martin JD, Askoxylakis V, Padera TP, Fukumura D, Boucher Y, Hornicek FJ, Grodzinsky AJ, Baish JW, Munn LL, Jain RK. Solid stress and elastic energy as measures of tumour mechanopathology. Nat Biomed Eng. 2016; 1.View Related Profiles.

Jones, Dennis
Nia, Hadi

PMID: 28966873; PMCID: PMC5621647; DOI: 10.1038/s41551-016-0004;

Blatter C, Meijer EF, Nam AS, Jones D, Bouma BE, Padera TP, Vakoc BJ. In vivo label-free measurement of lymph flow velocity and volumetric flow rates using Doppler optical coherence tomography. Sci Rep. 2016 07 05; 6:29035. PMID: 27377852; PMCID: PMC4932526; DOI: 10.1038/srep29035;

Jeong HS, Jones D, Liao S, Wattson DA, Cui CH, Duda DG, Willett CG, Jain RK, Padera TP. Investigation of the Lack of Angiogenesis in the Formation of Lymph Node Metastases. J Natl Cancer Inst. 2015 Sep; 107(9). PMID: 26063793; PMCID: PMC4651102; DOI: 10.1093/jnci/djv155;

Pereira ER, Jones D, Jung K, Padera TP. The lymph node microenvironment and its role in the progression of metastatic cancer. Semin Cell Dev Biol. 2015 Feb; 38:98-105. PMID: 25620792; PMCID: PMC4397158; DOI: 10.1016/j.semcdb.2015.01.008;

Liao S, Jones D, Cheng G, Padera TP. Method for the quantitative measurement of collecting lymphatic vessel contraction in mice. J Biol Methods. 2014; 1(2). PMID: 25512945; PMCID: PMC4264607; DOI: 10.14440/jbm.2014.26;

Holopainen T, López-Alpuche V, Zheng W, Heljasvaara R, Jones D, He Y, Tvorogov D, D'Amico G, Wiener Z, Andersson LC, Pihlajaniemi T, Min W, Alitalo K. Deletion of the endothelial Bmx tyrosine kinase decreases tumor angiogenesis and growth. Cancer Res. 2012 Jul 15; 72(14):3512-21. PMID: 22593188; DOI: 10.1158/0008-5472.CAN-11-1070;

Truman LA, Bentley KL, Smith EC, Massaro SA, Gonzalez DG, Haberman AM, Hill M, Jones D, Min W, Krause DS, Ruddle NH. ProxTom lymphatic vessel reporter mice reveal Prox1 expression in the adrenal medulla, megakaryocytes, and platelets. Am J Pathol. 2012 Apr; 180(4):1715-25. PMID: 22310467; PMCID: PMC3349900; DOI: 10.1016/j.ajpath.2011.12.026;

Jones D, Li Y, He Y, Xu Z, Chen H, Min W. Mirtron microRNA-1236 inhibits VEGFR-3 signaling during inflammatory lymphangiogenesis. Arterioscler Thromb Vasc Biol. 2012 Mar; 32(3):633-42. PMID: 22223733; PMCID: PMC3288963; DOI: 10.1161/ATVBAHA.111.243576;

Jones D, Min W. An overview of lymphatic vessels and their emerging role in cardiovascular disease. J Cardiovasc Dis Res. 2011 Jul; 2(3):141-52. PMID: 22022141; PMCID: PMC3195192; DOI: 10.4103/0975-3583.85260;

Jones D. Genetic engineering of a mouse: Dr. Frank Ruddle and somatic cell genetics. Yale J Biol Med. 2011 Jun; 84(2):117-24. PMID: 21698043; PMCID: PMC3117405

Jones D, Xu Z, Zhang H, He Y, Kluger MS, Chen H, Min W. Functional analyses of the bone marrow kinase in the X chromosome in vascular endothelial growth factor-induced lymphangiogenesis. Arterioscler Thromb Vasc Biol. 2010 Dec; 30(12):2553-61. PMID: 20864667; PMCID: PMC3106279; DOI: 10.1161/ATVBAHA.110.214999;

Luo Y, Xu Z, Wan T, He Y, Jones D, Zhang H, Min W. Endothelial-specific transgenesis of TNFR2 promotes adaptive arteriogenesis and angiogenesis. Arterioscler Thromb Vasc Biol. 2010 Jul; 30(7):1307-14. PMID: 20395596; PMCID: PMC2889154; DOI: 10.1161/ATVBAHA.110.204222;

Dai S, He Y, Zhang H, Yu L, Wan T, Xu Z, Jones D, Chen H, Min W. Endothelial-specific expression of mitochondrial thioredoxin promotes ischemia-mediated arteriogenesis and angiogenesis. Arterioscler Thromb Vasc Biol. 2009 Apr; 29(4):495-502. PMID: 19150880; PMCID: PMC2734510; DOI: 10.1161/ATVBAHA.108.180349;

Zhang H, He Y, Dai S, Xu Z, Luo Y, Wan T, Luo D, Jones D, Tang S, Chen H, Sessa WC, Min W. AIP1 functions as an endogenous inhibitor of VEGFR2-mediated signaling and inflammatory angiogenesis in mice. J Clin Invest. 2008 Dec; 118(12):3904-16. PMID: 19033661; PMCID: PMC2575835; DOI: 10.1172/JCI36168;

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 27 publications over 14 distinct years, with a maximum of 4 publications in 2018